Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Clinical trial NCT04198766 · RECRUITING

Trial details

NCT number: NCT04198766
Sponsor: Inhibrx Biosciences, Inc
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Solid Tumor Non-Small Cell Lung Cancer Head and Neck Cancer Melanoma Gastric Cancer Renal Cell Carcinoma Urothelial Carcinoma Resectable Non-Small-Cell Lung Cancer

Start date: 2019-12-10
Primary completion: 2033-07-01
Enrollment: 340

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.